Leucogen to prevent low white blood cells from ribociclib in early breast cancer
Part of Blood & lymphatic, Cancer, Skin clinical trials.
This trial tests if Leucogen can prevent neutropenia (low white blood cells) caused by ribociclib, a targeted therapy for hormone receptor-positive, HER2-negative early breast cancer. It may help you stay on treatment without delays or dose reductions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman with early breast cancer that is hormone receptor-positive and HER2-negative.
- You have had surgery to remove all cancer, and you have stage II (with certain features) or stage III disease.
- You have completed any needed chemotherapy or radiotherapy before joining.
- Your blood counts, kidney and liver function, and heart rhythm (QT interval) must be within safe ranges.
- You cannot have taken a CDK4/6 inhibitor before, and must avoid certain medications and fruits that interact with study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two medications—Shengbai Oral Liquid and Leucogen Tablets—to help raise white blood cell counts in breast cancer patients whose counts drop during cancer treatment. Both drugs aim to help your body recover faster and allow you to continue your cancer therapy on schedule.
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
This trial tests whether some people with early-stage, hormone-positive breast cancer can safely skip chemotherapy and instead receive a targeted pill (ribociclib) with hormone therapy. A special blood test looks for tiny pieces of tumor DNA to help guide treatment decisions.
This trial tests whether some people with hormone receptor-positive, HER2-negative early breast cancer can safely receive less chemotherapy when also taking the targeted drug ribociclib after surgery. You may qualify if you have a specific stage of breast cancer and are planning to take hormone therapy for at least 5 years.
This trial tests ribociclib, a targeted therapy, for women with hormone receptor-positive, HER2-negative breast cancer who still have cancer cells in the breast or lymph nodes after initial chemotherapy. It aims to reduce the chance of cancer coming back.
This trial looks at how well ribociclib works and why it may stop working over time in people with advanced, hormone-receptor–positive, HER2-negative breast cancer. It also analyzes blood and tissue samples to help researchers understand resistance patterns and improve future treatment decisions.
Hear when a new Ribociclib trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.